Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 29, 2024
Product Development
Market reaction to Intellia data suggests perfection remains bar for gene editing
Clinical Report: Celldex advances in a second urticaria type, Eledon’s mAb helps Type I diabetes patients become insulin-independent, and more
BioCentury | May 7, 2024
Product Development
Clinical report: Calliditas data provide mixed support for anti-fibrotic cancer mechanism
Plus: J&J aiming to replace bladder cancer surgery with TAR-210, and updates from Merck, GlycoMimetics, EyePoint and more
BioCentury | Apr 9, 2024
Discovery & Translation
AACR brings new modalities, new targets to glioblastoma
BioCentury identifies new CAR T cell designs, ADCs and other modalities, plus 37 preclinical targets for
BioCentury | Mar 19, 2024
Deals
AZ deepens radiopharma commitment via $2B Fusion takeout
Deal brings more momentum for α-emitters, with Fusion’s lead program contrasting Novartis’ β-emitting Pluvicto
BioCentury | Apr 21, 2023
Product Development
ADC advances at AACR: target diversity, optimizing internalization
BioCentury’s analysis of the AACR 2023 abstracts highlights innovation in antibody-drug conjugate design
BioCentury | Jan 31, 2023
Deals
Pfizer pencils in $15B in 2030 revenue from future deals
With COVID-19 revenue slowing down after record year in 2022, pharma still seeking BD transactions to meet revenue goal
BioCentury | Dec 9, 2021
Finance
F-Prime, Atlas back K36 with $30M to advance MM candidate
Newly launched K36 in-licensed potential first-in-class therapy from Novartis for multiple myeloma subset
BioCentury | Aug 28, 2021
Product Development
Aug. 27 Quick Takes: BioMarin gains first worldwide approval for achondroplasia therapy
Plus: Roche’s Tecentriq withdrawal, a16z’s seed fund, Lynk’s venture round and more
BioCentury | Aug 24, 2021
Deals
Aug. 23 Quick Takes: Pfizer, BioNTech look ahead to pediatric data after FDA approval of Comirnaty
Approval for COVID-19 vaccines from Zydus Cadila, Medigen-Dynavax; plus Sabatini fired, Clover’s U.S. beachhead and more
BioCentury | Jan 30, 2021
Regulation
Novartis subcutaneous mAb for MS, Incyte and Karyopharm oral cancer therapies backed by CHMP
Among the therapies to receive a positive opinion from EMA’s CHMP in January were drugs from Novartis, Incyte and Karyopharm that have convenient routes of administration. The agency
Items per page:
1 - 10 of 62